Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: blessedtobehere who wrote (49510)	1/21/2019 7:52:31 PM
From: stockdoc77	5 Recommendations Recommended By dorightbythem idahoranch1 JJINV li3511 patlawche11 Read Replies (2) \| Respond to of 63287

I think you misinterpet the remarks. The CRL letter itself is not sufficiently detailed to provide IMMU the roadmap needed to resolve all FDA issues. The letter is just the headlines. It will be in the follow up meeting the company has with the FDA where all that get's laid out. After that meeting, if the company keeps the sales force then they think they have a shot at quick approval, if they fire the sales force we are looking at a longer time frame. That will be the tell.